Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?

Annals of the Rheumatic Diseases

Volumn 67, Issue 10, 2008, Pages 1358-1359

  Saag, Kenneth G ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; COLLAGEN TYPE 2; CYTOKINE; ESTROGEN; ETIDRONIC ACID; MATRIX METALLOPROTEINASE; NERIDRONIC ACID; OSTEOCALCIN; PLACEBO; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TELOPEPTIDE; ZOLEDRONIC ACID;

AGING; BIOASSAY; BODY COMPOSITION; BONE REMODELING; CARTILAGE; COLLAGEN SYNTHESIS; CROSS LINKING; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; FOLLOW UP; HEALTH; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; JOINT CAVITY; JOINT RADIOGRAPHY; LONG TERM CARE; LOW BACK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPHYTE; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS; RISK BENEFIT ANALYSIS; SCLEROSIS; SPINE FRACTURE; TRABECULAR BONE;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 53149096201     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2008.089912     Document Type: Editorial

References (15)

1. Abramson SB, Honig S. Antiresorptive agents and osteoarthritis: more than a bone to pick? Arthritis Rheum 2007;56:2469-73.
2. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001;44:2201-10.
3. Evans CH, Mears DC. Binding of the bone-seeking agent 99mTc-1-hydroxyethylidene-1,1-diphosphonic acid to cartilage and collagen in vitro and its stimulation by Er3+ and low pH. Calcif Tissue Int 1980;32:91-4.
4. Edmonds-Alt X, Breliere JC, Roncucci R. Effects of 1-hydroxyethilene-1,1-diphosphonate and (chloro-4-phenyll-thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chondrocytes and synovial cells. Biochem Pharmacol 1985;34:4043-9.
5. Corrado A, Cantatore FP, Grano M, Colucci S. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol 2005;24:527-34.
6. Podworny NV, Kandel RA, Renlund RC, Grynpas MD. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 1999;26:1972-82.
7. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004;50:1193-206.
8. Guenther HL, Guenther HE, Fleisch H. The effects of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on collagen synthesis by rabbit articular chondrocytes and rat bone cells. Biochem J 1981;196:293-301.
9. Muehleman C, Green J, Williams JM, Kuettner KE, Thonar EJ, Sumner DR. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 2002;10:226-33.
10. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004;50:3516-25.
11. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P. Cline GA, Beary JF, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005;7:R625-33.
12. Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507.
13. Buckland-Wright JC, Messent EA, Bingham CO 3rd, Ward RJ, Tonkin C. A 2 year longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007;46:257-64.
14. Neogi T, Nevitt MC, Ensrud KE, Bauer D, Felson DT. The effect of alendronate on progression of spinal osteophytes and disc space narrowing. Ann Rheum Dis 2008;67:1427-30.
15. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. 2008;358:1304-06.